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ABSTRACT
In Brazil, thalidomide has been used virtually without interruption since it was launched as a new 
and revolutionary sedative drug in 1956. After 1965, when its efﬁ  cacy to treat erythema nodosum 
leprosum (ENL) was discovered, it was regarded as an essential drug because the prevalence of 
Hansen’s disease is high in the country. In the 1990s and thereafter myriad novel therapeutic 
uses for thalidomide (autoimmmune diseases, multiple myeloma, aphthous ulcers in AIDS, and 
others) have emerged owing to its immunomodulatory and antiangiogenic activities. Owing to 
a marked teratogenicity, however, the prescription and dispensing of thalidomide to patients is 
strictly controlled in Brazil and elsewhere. Notwithstanding the stringent regulations, a number 
of post-1965 cases of thalidomide embryopathy have occurred in Brazil. In 2003, a federal law 
(Law 10.651/2003) prohibited the sale and dispensing of thalidomide in commercial pharmacies. 
The law, however, made no provision for teratogenic drug analogues such as lenalidomide and 
pomalidomide, which have been cleared for marketing in the USA, Europe and other countries. 
Although they are much more expensive than thalidomide, the clinical superiority of novel ana-
logues over thalidomide in multiple myeloma and other conditions remains unproven. Therefore, 
so far novel analogues can be considered as thalidomide “me too” drugs. This author strongly 
recommends that an amendment to the current law prohibiting the sale and dispensing of thalid-
omide in commercial pharmacies be extended to thalidomide analogues. Moreover, we consider 
that a demonstration of clinical superiority over thalidomide (through gold-standard comparative 
efﬁ  cacy trials) should be an essential requirement for registration of any teratogenic analogue.
KEYWORDS: Lenalidomide; Pomalidomide; Cost Effectiveness; Multiple Myeloma; 
Teratogenic Drugs; Thalidomide Embryopathy
RESUMO
No Brasil, a talidomida tem sido usada praticamente sem interrupção desde o seu lançamento 
como novo e revolucionário medicamento sedativo em 1956. Depois de 1965, quando a sua 
eﬁ  cácia para tratar o eritema nodoso (ENL) foi descoberta ela tem sido considerada como medi-
camento essencial porque a prevalência da hanseníase é alta no país. Nos anos 1990 e depois, 
surgiu uma diversidade de novos usos terapêuticos para a talidomida (doenças auto-imunes, 
mieloma múltiplo, ulcerações aftosas na AIDS, e outras) em virtude das suas atividades anti-
inﬂ  ammatórias e anti-angiogênicas. Por causa da teratogenicidade, a prescrição e dispensação 
da talidomida são rigorosamente controladas no Brasil e outros países. Em que pese o rigor da 
regulamentação, muitos casos de embriopatia pela talidomida ocorreram no Brasil após 1965. 
Em 2003, uma lei federal (Lei 10.651/2003) proibiu a venda e a dispensação de talidomida em 
farmácias comerciais. A lei, entretanto, não faz referência aos análogos teratogênicos tais como 
lenalidomida e pomalidomida cuja comercialização foi autorizada nos EUA, Europa e outros 
países. Embora sendo muito mais caros que a talidomida, a superioridade clínica dos novos 
análogos em relação à talidomida no mieloma múltiplo e outras doenças não foi demonstrada. 
Portanto, até agora os novos análogos podem ser considerados como medicamentos “me too”. 
Recomenda-se enfaticamente uma emenda à lei atual que estenda a proibição da venda e 
dispensação em farmácias comerciais aos análogos da talidomida. Deve-se exigir também a 
demonstração de superioridade clínica em comparação com a talidomida (por meio de ensaios 
clínicos comparativos de padrão ouro) para registro de qualquer análogo teratogênico.
PALAVRAS-CHAVE: Lenalidomida; Pomalidomida; Custo Efetividade; Mieloma Múltiplo; 
Medicamentos Teratogênicos; Embriopatia por Talidomida
DOI:10.3395/vd.v1i3.57h
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Introduction
Thalidomide holds a unique position in the Brazilian drug 
regulatory framework. It is the only medicine that is regulated 
by a speciﬁ  c federal law (Law 10.651, 16 April, 2003)1. The law 
forbids the sale and/or dispensing of thalidomide in commer-
cial pharmacies. It also states that thalidomide shall be distrib-
uted to public health units/hospitals and dispensed to patients 
through programs approved by the federal health authority 
(Ministry of Health)1. A copy of a physician’s written order (on a 
special numbered prescription order form) must be retained by 
the public health unit or hospital pharmacy and sent to the lo-
cal sanitary surveillance ofﬁ  ce. The Ministry of Health programs 
through which thalidomide can be distributed and dispensed are 
those for Hansen’s disease, sexually transmitted diseases and 
AIDS (i.e., aphthous ulcers in AIDS patients) and chronic degen-
erative diseases (i.e., for lupus erythematosus and graft-versus-
host disease)1,2. In addition, the law states that package labeling 
must warn that thalidomide is strictly prohibited for pregnant 
women and for women at risk of becoming pregnant. The pack-
age inserts must also provide detailed information about the 
drug and its proven teratogenic effects, and include a responsi-
bility term that must be signed by prescribers and patients. To 
receive thalidomide, patients must present two documents at 
the public health unit or hospital pharmacy: a special prescrip-
tion order and a signed responsibility term. Moreover, federal 
health programs must provide full information on the terato-
genic risks of thalidomide, offer advice on pregnancy prevention 
methods, and give contraceptives to women of childbearing age 
under treatment for hanseniasis or any other disease for which 
the drug is indicated and prescribed1. Law 10.651/2003, how-
ever, made no provision for thalidomide analogues the ﬁ  rst of 
which – lenalidomide – entered phase-III clinical trials at about 
the time the thalidomide law was enacted in Brazil1. Lenalido-
mide (brand name Revlimid™) was developed by a global bi-
opharmaceutical company (Celgene Corporation, NJ) and ﬁ  rst 
approved by the US FDA on 27 December 20053. Approved thera-
peutic indications for Revlimid™ were the treatment of transfu-
sion-dependent patients with myelodysplastic syndrome (with 
deletion 5q chromosomal abnormalities) (December 2005), 
treatment of multiple myeloma (in combination with dexa-
methasone) on 29 June 2006, and more recently (5 June 2013), 
treatment of relapsed or refractory mantle cell lymphoma3. 
On 8 February 2013, pomalidomide (brand name Pomalyst™), 
another thalidomide analogue developed by Celgene Corp., re-
ceived FDA approval for the treatment of relapsed or refractory 
multiple myeloma4. Lenalidomide and pomalidomide (Figure 1) 
share with thalidomide both therapeutic (immunomodulatory) 
and teratogenic properties.
Thalidomide uses, misuses and current 
regulatory status
Thalidomide was developed by a German pharmaceutical 
company (Chemie Grünenthal GmbH, founded in 1946) and en-
tered the market as a new and revolutionary sedative drug in the 
mid-1950s5,6,7,8,9. Compared to the sleeping pills and tranquiliz-
ing drugs available until then (e.g., barbiturates and bromides), 
thalidomide seemed to be safe. Chemie Grünenthal toxicolo-
gists claimed that they “could not ﬁ  nd a dose high enough to 
kill a rat”, and most physicians believed that suicide attempts 
with overdoses of thalidomide, unlike those with barbiturates, 
would be doomed to failure5,6,7,8,9. Although a peripheral neu-
ropathy was noted in patients treated with thalidomide, the 
manufacturer denied any causal relationship between the drug 
and this neurological condition and continued to claim that its 
product was safe7. In November 1961, however, Widukind Lenz, 
a pediatrician and medical geneticist, reported that an ongoing 
outbreak of birth defects (phocomelia, a pre-axial reduction 
of limbs, and amelia, or absence of limbs), seldom recorded 
before the mid-1950s, was due to thalidomide use during preg-
nancy5,6. The link between intake of thalidomide during gesta-
tion (ﬁ  rst trimester) and congenital anomalies – noted by Lenz 
in Germany – was subsequently conﬁ  rmed by McBride in Aus-
tralia10 and Smithells in the UK11. Within a few weeks of these 
ﬁ  rst reports, thalidomide was withdrawn from the market in 
Germany and Great Britain. In Brazil, Belgium, Canada, Italy, 
Japan and a few other countries thalidomide continued to be 
sold for several months thereafter 5,6,8,9. A suspicion about the 
neurological side-effects (peripheral neuropathy) delayed the 
approval of thalidomide in the USA, so that it had not been ap-
proved for marketing when the drug-induced epidemic of birth 
defects came to light. Thanks to Dr Frances Kelsey, a stubborn 
FDA ofﬁ  cial, the biggest pharmaceutical market in the world 
was spared a thalidomide disaster. Although not being sold 
in pharmacies, thalidomide caused a few cases of congenital 
anomalies in the USA due to the pre-approval distribution of 
free drug samples to physicians, a promotional practice intend-
ed to “seed the market”5,6,7,8,9.
Babies with a thalidomide embryopathy phenotype that 
were born 9 or more months after the drug was banned in 
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Figure 1. Novel thalidomide analogues lenalidomide and po-
malidomide. The quest for safer (not teratogenic) and more 
effective thalidomide analogues has not been successful so far.h
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Germany and the UK were considered by Lenz as “avoidable 
cases”, many of which were from Brazil and Japan5,6,7,8,9. Tha-
lidomide was banned worldwide in the mid-1960s, but its use 
was never completely discontinued in Brazil owing to an unex-
pected new therapeutic indication. In 1965, Jacob Sheskin, an 
Israeli doctor, prescribed thalidomide as a sedative for patients 
with hanseniasis and observed that it ameliorated symptoms of 
erythema nodosum leprosum (ENL), or Hansen’s disease type-2 
reaction12. Sheskin’s serendipitous discovery that thalidomide 
was effective in the treatment of ENL (published as a series 
of cases) was further conﬁ  rmed by several controlled clinical 
trials. As the prevalence of hanseniasis in Brazil is high, the 
health authorities have listed thalidomide as an essential drug.
New cases of thalidomide embryopathy in babies born af-
ter 1965 (i.e., Lenz’s “avoidable cases”) remained virtually 
unnoticed until the mid-1990s. In 1994, two Brazilian non-
governmental organizations (NGOs) — MORHAN (Movement 
for the Integration of People Affected by Hansen Disease) and 
ABPST (Association of People with Thalidomide Syndrome) — 
performed an active search and found 61 people born after 
1965 with birth defects compatible with thalidomide embryo-
pathy13,14. A further study by Castilla et al.15 conﬁ  rmed that at 
least 33 of these 61 (post-1965) cases of congenital anomalies 
were consistent with a diagnosis of thalidomide embryopathy.
At about that time (mid-1990s) a set of experimental and 
clinical studies shed new light on the anti-inﬂ  ammatory (e.g. 
anti-TNF) and antiangiogenic properties of thalidomide16. Be-
tween the late 1970s and early 2000, a series of clinical stud-
ies showed that thalidomide induced symptomatic remission of 
aphthous stomatitis17,18,19,20, Behçet’s diseasei  21,22 and prurigo 
nodularis23,24, and was beneﬁ  cial in the treatment of graft-ver-
sus-host disease after transplantation25, autoimmune diseases 
such as cutaneous and systemic lupus erythematosus26,27,28, 
and certain conditions associated with HIV infection, such as 
aphthous ulcers and wasting syndrome29,30,31. A landmark in the 
emergence of thalidomide as a potentially useful drug in the 
treatment of some types of cancerii was the demonstration 
that it possessed antiangiogenic activity.
A study by Robert D’Amato and coworkers, published in 
1994, revealed that thalidomide was an inhibitor of angiogen-
esis in a rabbit cornea assay32. Solid tumors depend on the 
proliferation of new blood vessels to increase in size, and thus 
the malignant tissue produces substances that promote its 
vascularization33. Consequently, inhibition of angiogenesis was 
regarded as a promising pharmacological target for developing 
an entirely new class of effective anticancer agentsiii 33. Along 
this line, the next step was to test thalidomide in patients with 
relapsed and/or refractory multiple myeloma (MM)iv 34.
In an apparent reaction to an uncontrolled use of thalido-
mide entering the country illegally for a variety of new thera-
peutic indications, in 1998 the FDA approved the use of tha-
lidomide for ENL, and some years later, in 2006, for patients 
newly diagnosed with MMv 39.
In Brazil, deep concerns raised by the uncovering of several 
post-1965 cases of thalidomide-compatible birth defects, and 
the emergence of new uses, prompted the Ministry of Health 
to prohibit the prescription of thalidomide to any woman of 
childbearing age (from menarche to menopause), except in 
very special circumstances and under strictly controlled con-
ditions41. In 2002, the the Ministry of Health published clinical 
guidelines for the use of thalidomide in graft-versus-host dis-
ease, lupus erythematosus and MM2. As already mentioned, in 
2003 the sale and dispensing of thalidomide in Brazil began to 
be regulated by a speciﬁ  c federal law1. No new case of thalido-
mide-compatible birth defects was recorded between 1997 and 
200514. Nonetheless, in 2005 a woman who took the drug for ENL 
gave birth to a male baby with thalidomide embryopathy, and 
in 2006 three additional cases were recorded: a female born to 
a woman who used thalidomide for ENL, and male twins born to 
a mentally disturbed 17-year-old girl who took pills prescribed 
for her mother, a patient with MM42,43. Moreover, a proactive 
surveillance found two babies with a thalidomide embryopathy 
phenotype born in 2007 — a male and a female. In both cases, 
however, the mothers denied any use of thalidomide42,43. As far 
as this author is aware, the most recent case of thalidomide 
embryopathy occurred in the state of Maranhão in 2010vi 44. A 
patient with ENL, who had taken thalidomide during gestation, 
gave birth to a female baby with bilateral upper and lower limb 
reduction defects44. In 2011, a new regulation controlling the 
dispensing and prescription of thalidomide (introducing a more 
effective control on drug dispensing for off-label indications) 
was issued and put into effect by ANVISA, the health regulatory 
agency of Brazil45 (Table 1, Figure 2).
i Behçet’s disease or syndrome is a rare immune-mediated small-vessel systemic vasculitis, the symptoms of which include painful oral aphthous ulcers, genital 
ulcerations, cutaneous pustular lesions and uveitis.
ii As several antineoplastic drugs used in the mid-1960s were also teratogenic agents, some clinical researchers speculated that thalidomide, a potent human 
teratogen, might also possess antitumor properties. Still in the 1960s, thalidomide was trialed in patients with different types of cancer, but investigators found 
little or no evidence of an effective therapeutic response35,36.
iii In 1971, Judah Folkman highlighted that solid tumors required neovascularization (angiogenesis) for growth and survival33. Since then, inhibition of new 
blood vessel growth has become a potential target for an effective anticancer therapy. Today, several drugs that inhibit angiogenesis are used in oncology to 
treat different types of tumors. Binding of signaling molecules (e.g., vascular endothelial growth factor, VEGF) to the surface of endothelial cells is required for 
angiogenesis. Inhibition of angiogenesis can be achieved by using monoclonal antibodies (e.g., bevacizumab) that speciﬁ  cally recognize and bind to VEGF, or by 
other drugs (e.g., sorafenib and sunitinib) that block receptors on the surface of endothelial cells (or other proteins in the downstream signaling pathways)37,38.
iv Multiple myeloma, also known as plasma cell myeloma, is an abnormal (malignant) proliferation of plasma cells that can affect the bones, the immune 
system, the kidneys and the red blood cell count.
v The incidence of Hansen’s disease is very low in the USA. In 2007, 109 cases of Hansen’s disease (most of which were imported) were reported to CDC-USA, 
whereas 249,009 cases occurred worldwide. Of all cases reported to the WHO in 2008, 77% were from Brazil, India and Indonesia40. The rarity of ENL in the USA 
explains why the FDA had no interest in approving thalidomide. FDA approval came three decades after Sheskin had reported that the drug was effective in 
treating type II reaction symptoms.
vi This case of birth defects — compatible with thalidomide use — was reported to the Ministry of Health (Department of Epidemiological Surveillance/
Hanseniasis Control Program, and the National Agency of Health Surveillance - ANVISA).h
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Innovative and “me too” drugs
A “me-too” drugvii is a drug that uses essentially the same 
therapeutic mechanism of action as an existing one, offering 
no signiﬁ  cant additional beneﬁ  t in terms of efﬁ  cacy and/or 
safety (i.e., they are not clinically superior). Many “me-too” 
drugs are chemically related to the prototype and hence are 
also structurally very similar to one or more drugs already 
on the market, with only minor differences46,47. In fact, “me-
too” drugs largely duplicate the therapeutic action of drugs 
that are already available. As the R&D of pharmaceuticals is 
a lengthy process, a “me-too” drug may result from a parallel 
drug development (i.e., despite being approved for marketing 
later, a “me-too” drug might have entered development long 
before the innovative drug began to be used in clinical prac-
tice). Nonetheless, in a number of cases “me-too” drugs are 
intentionally developed imitations of innovative medicines. 
The R&D process of a “me-too” drug is more predictable (or 
less risky) than that of an innovative medicine. At any rate, 
imitations are developed to compete with the pioneer drug 
and other existing medicines.
The deliberate development of “me-too” drugs has been 
questioned because these drugs do not bring additional ben-
eﬁ   ts to patients46,48. Focusing on a market for “me-too”s, 
pharmaceutical companies use funds and resources that could 
otherwise be applied to the development of innovative medi-
cines, many of which are desperately needed for a number 
of morbid conditions, including the neglected diseases. Along 
this line, Marcia Angell48 and others proposed that a requisite 
for new drug approval by national regulatory agencies should 
be evidence not only of efﬁ  cacy compared with placebo, but 
also of clinical superiority (efﬁ  cacy and/or safety) to existing 
therapies. Such a proposal is controversial, and some authors 
have defended “me-too” drugs, arguing that non-innovative 
vii “Me-too” drugs are sometimes also called “follow-on” drugs.
Table 1. Timeline of landmarks on thalidomide and analogue use and regulation
Year Landmark event
1956 Chemie Grünenthal GmbH launched thalidomide as a new sedative drug. 
1961 Widukind Lenz reported that the use of thalidomide by pregnant women was associated with the outbreak of phocomelia/amelia in Germany.
Thalidomide was withdrawn from the market in Germany, UK and other countries.
1965 Jacob Sheskin reported that thalidomide ameliorates ENL painful symptoms.
1994 An NGO survey revealed a number of cases of birth defects compatible with thalidomide embryopathy among people born in Brazil after 1965.
A study by Robert D’Amato et al. revealed that thalidomide inhibits angiogenesis.
1998 The US FDA approved thalidomide use in ENL.
1999 A clinical trial by Singhal et al. showed that thalidomide is active against advanced multiple myeloma.
2003 Brazil federal law forbade thalidomide sales and dispensing in commercial pharmacies and stated that it should be distributed and dispensed 
only through Ministry of health programs. A strict control on thalidomide prescription and dispensing is established.
2005 The US FDA ﬁ  rst approved lenalidomide (Revlimid™) for myelodysplastic syndrome with deletion of 5q chromosomal abnormality.
Despite the federal law, and strict control on the dispensing of thalidomide established by lower level regulation, new cases of babies born 
with thalidomide embryopathy continued in Brazil (2005–2010).
2006 The US FDA approved thalidomide use in relapsed and/or refractory MM.
The US FDA (June 29) approved lenalidomide for use in combination with dexamethasone in patients with MM. 
2010 The Brazilian health regulatory agency (ANVISA) denied approval for lenalidomide use in MM and myelodysplastic syndrome. 
2011 New rules on thalidomide control, including those regarding the dispensing of thalidomide for off-label indications, were put into effect 
by ANVISA.
2012 After evaluating a request for reconsideration ﬁ  led by the pharmaceutical company, ANVISA conﬁ  rmed its previous decision (denial of 
approval) regarding lenalidomide registration.
2013 The US FDA approved pomalidomide (Pomalyst™) for relapsed and/or refractory MM.
Figure 2. A search in the PubMed database (on July 15th, 2013) 
revealed that thalidomide ( ) is one of the most studied drugs 
(7800 publications, 263 in 2013). Lenalidomide ( ) and poma-
lidomide (●) with 1845 (259 in 2013) and 143 (30 in 2013), pub-
lications, respectively, are far less studied. Landmark events 
indicated by arrows and numbers are as follows: 1 - 1961: 
teratogenic effects of thalidomide reported by Lenz; 2 - 1965: 
Sheskin reported that thalidomide ameliorated ENL symptoms; 
3 - 1994: D’Amato et al demonstrated that thalidomide had 
antiangiogenic activity; 4 -1998: US FDA approved thalidomide 
for ENL; 5 - 2003: Thalidomide law was enacted in Brazil; 6 
- 2005: US FDA approved thalidomide for myelodysplastic syn-
drome and 2006 thalidomide and lenalidomide were approved 
for multiple myeloma.
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medicines enhance competition and stimulate the lowering of 
prices, which is ultimately beneﬁ  cial to consumers.
One difﬁ  culty in imposing restrictions for launching a puta-
tive “me-too” on the market is that eventual differences be-
tween a structurally related drug and its prototype may appear 
only after they have been in large-scale use for some time. 
Drug effectiveness (clinical beneﬁ  t under real conditions of use 
that differ from those of controlled trials) and certain aspects 
of drug safety are not fully disclosed by pre-marketing phase-
III clinical trials. Post-marketing pharmacovigilance is required 
to detect very rare, albeit severe, adverse drug reactions and 
for estimating their incidencesviii 49. The antidiabetic drug tro-
glitazone, for instance, was withdrawn from the market owing 
to an increased occurrence of idiosyncratic drug-induced liver 
injury (DILI). Furthermore, two other thiazolidinediones and 
putative “me-too” oral hypoglycemic drugs (pioglitazone and 
rosiglitazone) were considered as being negative compounds 
for DILIix 52.
ANVISA’s viewpoint on the registration of “me too” drugs 
states that: “... it is difﬁ  cult or even impossible to classify a 
(new) medicine as a “me too” drug on the occasion it is (ﬁ  rst) 
registered because some of its attributes that would allow us 
to make this classiﬁ  cation can only be (fully) assessed after 
the product is marketed and used in large scale”x 53. Owing 
to this fact, and also because “current Brazilian laws do not 
support denying registration of new drugs based on such ar-
gument”, ANVISA does not necessarily reject applications for 
drugs that are apparently “me-too”s of medicines already on 
the market53.
Another key problem with putative “me-too” drugs is that 
pharmaceutical companies, in an attempt to boost sales, do 
not adequately inform physicians and consumers about the de-
gree of similarity of their products to existing drugs. On the 
contrary, companies generally claim that their (“me-too”) 
products are in some way “better” than pioneer drugs, even 
when this statement is not supported by adequately designed 
and conducted comparative efﬁ  cacy studies. Along this line, 
Angell48 pointed out that many structurally related (“me-too”) 
drugs are never tested at equivalent doses to show that there 
are signiﬁ  cant differences in clinical outcomes for some pa-
tients. Thus, in most cases, companies’ claims that “patients 
respond differently to ’me-too’ drugs is merely an untested 
– and self-serving – hypothesis”48.
Comparative efﬁ  cacy and safety of thalidomide 
analogues versus thalidomide
A key problem regarding the safety of any thalidomide 
analogue is to ﬁ  nd out whether it, too, has teratogenic prop-
erties. This question is not easily answered by routine pre-
clinical studies because rodents are known to be refractory 
to thalidomide-induced teratogenicity, and rabbits — albeit 
more susceptible than rats — do not exhibit the same pat-
tern of severe malformations as those found in primates54,55,56. 
A comparative developmental toxicity study of thalidomide 
and lenalidomide in rabbits showed that the former caused 
fetal structural anomalies (limb defects and others) in the ab-
sence of overt maternal toxicity, whereas the latter did not 
increase the incidence of malformations and produced other 
embryotoxic effects (prenatal growth retardation and embryo 
deaths) only at maternally toxic doses. These results were 
initially misinterpreted as an indication that lenalidomide 
would be less teratogenic than thalidomide. Moreover, authors 
stated in their conclusions that developmental toxicity stud-
ies on lenalidomide versus thalidomide would conﬁ  rm that “… 
structure–activity relationships may not predict maternal or 
developmental effects”54. A further non-human primate study, 
however, revealed that lenalidomide given orally to monkeys 
(at non-maternally toxic doses) caused congenital anomalies 
(short limbs; bent digits, wrist and/or tail; supernumerary or 
absent digits) similar to those produced by thalidomide in the 
same studyxi 55.
Thalidomide and lenalidomide are effective, both as single 
agents and in combination with other agents, when used to 
treat patients with relapsed and/or refractory MM. A combi-
nation of thalidomide, dexamethasone and cyclophosphamide 
has been used as a non-myelosuppressive induction regimen 
for MM patients eligible for autologous stem cell transplanta-
tion (ASCT), while combining melphalan (a nitrogen mustard 
alkylating agent), prednisone and thalidomide has become a 
treatment option for newly diagnosed MM patients ineligible 
for ASCT60. According to a recent review, ongoing trials contin-
ue to investigate novel thalidomide-based regimens to further 
optimize thalidomide use in the management of MM60.
Although several clinical studies showed that lenalidomide 
(e.g., lenalidomide plus dexamethasone) is effective in the 
treatment of MM61, no randomized trial has compared the efﬁ  -
cacy and safety of lenalidomide-based versus thalidomide-based 
viii This is illustrated by idiosyncratic drug-induced liver injury (DILI). DILI is the most common single adverse drug reaction (ADR), which led to its withdrawal 
from the market49. Idiosyncratic DILI is a rare (10-3 to 10-4) ADR that cannot be predicted by pre-clinical animal studies and is unlikely to be detected in typical 
phase-III clinical trials (involving 102 to 103 patients).
ix All three thiazolidinediones are oral hypoglycemic agents, agonists of PPAR- (peroxisome proliferator-activated receptor gamma) and possess anti-
inﬂ  ammatory properties. After a lengthy debate, rosiglitazone was removed from the market in many countries owing to post-marketing evidence that it 
increases the risk of myocardial infarct50. Recent post-marketing studies also provided evidence that pioglitazone and rosiglitazone enhanced the risk of bladder 
cancer in diabetic patients who used these drugs for one or more years51.
x The viewpoint of the Brazilian agency of health surveillance, ANVISA, on “me too” drugs was, to some extent, based on its advisory technical committee on 
medicines (CATEME) report.
xi The mechanism of the teratogenic action of thalidomide and its remarkable species-speciﬁ  city remained a complete mystery for nearly ﬁ  ve decades. 
Recently, a study by Ito et al.57,58 has started to decipher this enigma. Ito et al. identiﬁ  ed cereblon (encoded by the CRBN gene) as a thalidomide-binding 
protein. Thalidomide binding to CRBN and inhibiting the associated ubiquitin ligase activity is the ﬁ  rst step in a chain of events that leads to limb malformations 
in chicks, ﬁ  sh (ﬁ  ns), rabbits and primates but not in rats and mice. Along this line, recent studies have suggested that CRBN expression is required for anti-
myeloma activity of lenalidomide, pomalidomide and thalidomide59. Therefore, it is possible that, mechanistically, teratogenicity and the antimyeloma activity 
of thalidomide analogues are two sides of the same coin.h
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regimens. A retrospective (“case-control”) study by Gay et al.64 
compared the efﬁ  cacy and toxicity of lenalidomide plus dexa-
methasone (len/dex) versus thalidomide plus dexamethasone 
(tha/dex) as initial therapy for newly diagnosed MM, and sug-
gested that the former regimen would be somewhat more effec-
tive than the latter (thal/dex). Nonetheless, retrospectivexii and 
non-randomized studies are notoriously weak in supporting gen-
eral conclusions about the clinical superiority of one drug over 
another in the treatment of MM. Randomized and controlled 
prospective trials are still necessary to compare the efﬁ  cacy 
and safety of these two therapeutic regimens.
Pomalidomide has also been shown to be effective in re-
lapsed and/or refractory MM.
A variety of clinical studies have indicated that lenalido-
mide and pomalidomide, similarly to thalidomide, are im-
munomodulatory and antiangiogenic drugs that are not only 
effective in MM but also in myelodysplastic syndrome, lupus 
erythematosus, and several other morbid conditions. As far as 
this author is aware, however, no randomized clinical trial of 
thalidomide versus its novel analogues (lenalidomide or poma-
lidomide) for the aforementioned indications has so far been 
reported or is ongoing61,62,63.
Thalidomide and lenalidomide are associated with side-ef-
fects such as neutropenia; thrombocytopenia; peripheral neu-
ropathy; venous thromboembolism; syncope; bradycardia; skin 
reactions, including Stevens–Johnson syndrome; somnolence and 
dizziness55,64. Gay et al.’s non-randomized “case-control” study 
indicated that similar proportions of patients in thalidomide- 
and lenalidomide-regimen groups (MM treatment) experienced 
at least one grade 3 or 4 adverse event (AE) (57.5% vs 54.6%, 
P=0.568). Len/dex-treated patients experienced more hemato-
logic AEs, mainly neutropenia (14.6% vs 0.6%, P < 0.001), while 
the most common AEs among tha/dex-patients were venous 
thromboembolism (15.3% vs 9.2%, P  = 0.058) and peripheral 
neuropathy (10.4% vs 0.9%, P < 0.00165. An increased number 
of secondary primary malignancies have also been reported in 
several studies using lenalidomide maintenance65.
In July 2010, ANVISA rejected a new drug application for 
lenalidomide use in MM and myelodysplastic syndromes66. On 
that occasion, the advisory technical committee on medicines 
(“CATEME”) had recommended the agency not to approve le-
nalidomide for marketing, as no evidence (from sound com-
parative clinical trials) was presented to show that it was 
clinically superior to thalidomide-based regimens adopted in 
the treatment of MM and myelodysplastic syndrome66. The 
company ﬁ  led a reconsideration request in July 2010, and in 
December 2012 ANVISA conﬁ  rmed its previous decision to deny 
lenalidomide registration in the country66.
In summary, so far unequivocal evidence is lacking to sup-
port any claim that thalidomide analogues are more effective 
than their prototype drug (thalidomide) for MM or any other 
clinical indication.
The cost of novel thalidomide analogues to the Brazilian 
Uniﬁ  ed Health System
New drugs such as bortezomib (brand name VelcadeTM, the 
ﬁ  rst proteasome inhibitor used in therapeutics) have become 
available for the treatment of MM and other chronic diseases, 
and concern has grown over the rising costs of treatments. The 
cost-effectiveness of MM treatment regimens, for instance, has 
been examined and compared by several recent studies. A study 
by Garrison et al.67 addressed the problem of the cost-effective-
ness of novel regimens for MM (transplant-ineligible patients), 
such as when melphalan (M) plus prednisone (P) is combined 
with bortezomib (VMP) and with thalidomide (MPT), both with 
lenalidomide maintenance (MPR-R) and without lenalidomide 
maintenance (MPR). The authors estimated lifetime costs (in 
US dollars) as high as $119,102, $142,452 and $248,358 with 
VMP, MPT and MPR-R, respectively. Ashraf Badros69 also estimat-
ed that, owing to the high cost of lenalidomide tablets, treat-
ment of MM with this thalidomide analogue would cost $163,381 
(US dollars) per year for the average patient.
Although the cost-effectiveness of current treatment regi-
mens for MM is still a matter of debate, thalidomide-based reg-
imens seem to be much more cost-effective than those based 
on its novel analogue. In Brazil, where thalidomide is manufac-
tured by a state-owned pharmaceutical industry (FUNED-MG), 
production costs are very low. The cost of a thalidomide tablet 
to the Brazilian Ministry of Health is approximately 0.20 (Bra-
zilian) R$ (equivalent to about 0.08 USD), whereas in the USA 
– where it is manufactured by a private company — a similar 
tablet costs about 10.00 USD (equivalent to about R$ 24.4) 
i.e., in the USA thalidomide is 122 times more expensive than 
in Brazil. For the Brazilian public health system (SUS), there-
fore, the difference between the costs of thalidomide- and 
lenalidomide-based treatment regimens for MM and other 
chronic diseases is tremendous.
Conclusion
As previously mentioned, the law (No. 10.651/2003) pro-
hibits sales and imposes restrictions on the dispensing and dis-
tribution of thalidomide but makes no provision for its terato-
genic analogues. Notwithstanding the fact that lenalidomide 
has recently received a denial approval decision, sooner or 
later ANVISA will approve the marketing of novel thalidomide 
analogues. If the thalidomide law remains unchanged, a worry-
ing scenario can be foreseen. Current law does not prohibit the 
sale and dispensing of thalidomide (teratogenic) analogues in 
commercial pharmacies. Moreover, new product promotion by 
companies is likely to increase the frequency with which ana-
logues are prescribed, regardless of their cost-effectiveness.
For the sake of coherent drug regulation, the current law 
must be amended so that restrictions on thalidomide sales, dis-
tribution and dispensing are extended to those analogues that 
are proven or suspected to be human teratogens. Additionally, 
xii Gay et al.’s investigation64 was a “case-control” designed study based on the Mayo Clinic’s (USA) medical records.h
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a clause should be included stating that thalidomide analogues 
can only be registered in the country if gold-standardxiii com-
parative clinical trials demonstrate that they are clinically su-
perior (in terms of efﬁ  cacy and/or safety) to thalidomide-based 
(optimized) therapeutic regimens. The foregoing legal provision 
is needed to strengthen regulatory decisions that make excep-
tions to ANVISA’s rule of not rejecting approvals for marketing 
based merely on the fact that the drugs are putative “me-too”s 
(e.g., lenalidomide). It is of note that the “me-too” supporters’ 
argument — that imitation medicines stimulate competition, 
thereby contributing to a reduction in drug prices — does not 
hold true for thalidomide and its analogues. In this particular 
case, the costs of treatment regimens are, in one way or anoth-
er, covered predominantly by the public health system. It seems 
fair, therefore, that cost-effectiveness should be a requisite for 
the registration of novel thalidomide analogues.
In conclusion, restrictions imposed by current law on the 
sale and dispensing of thalidomide must be extended to its 
teratogenic analogues, otherwise a door is open to approve 
costly “me-too” drugs that are not clinically superior to their 
prototype medicine. Needless to say, the costs of expensive 
thalidomide “me-too” drugs are likely to be met predominant-
ly, if not entirely, by the public health system.
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